Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cipla
Chubb
Fish and Richardson
Farmers Insurance
Argus Health

Generated: June 16, 2019

DrugPatentWatch Database Preview

Litigation Details for Barkan Wireless IP Holdings, L.P. v. Samsung Electronics Co., Ltd. (E.D. Tex. 2018)

« Back to Dashboard

Barkan Wireless IP Holdings, L.P. v. Samsung Electronics Co., Ltd. (E.D. Tex. 2018)

Docket ➤ Try a Free Trial Date Filed 2018-01-30
Court District Court, E.D. Texas Date Terminated
Cause 35:271 Patent Infringement Assigned To James Rodney Gilstrap
Jury Demand Both Referred To
Parties BARKAN WIRELESS IP HOLDINGS, L.P.; CELLCO PARTNERSHIP D/B/A VERIZON WIRELESS; DAVID KEYZER; ROBERT W FAULKNER; SAMSUNG ELECTRONICS AMERICA, INC.; SAMSUNG ELECTRONICS CO., LTD.; VERIZON COMMUNICATIONS, INC.
Patents 10,041,044
Attorneys Aaron Wainscoat; Blaine Andrew Larson; Claire Abernathy Henry; Douglas Ron Wilson; Elizabeth L DeRieux; Erik R Fuehrer; James M Heintz; Kevin Paul Anderson; Mark D Fowler; Matthew R Berry; Max Lalon Tribble , Jr; Melissa Richards Smith; Michael E Jones; Michael F Heim; Patrick Colbert Clutter , IV; Patrick S Park; Robert Allan Bullwinkel; Sidney Calvin Capshaw , III; Thomas John Ward , Jr; William D. O'Connell
Firms Capshaw DeRieux, LLP; DLA Piper US LLP Palo Alto; Duane Morris LLP Washington; Gillam and Smith LLP; Heim, Payne & Chorush, LLP-Austin; Potter Minton, a Professional Corporation; Susman Godfrey LLP; Susman Godfrey, LLP Seattle; Susman Godrey LLP New York; Ward, Smith & Hill, PLLC
Link to Docket External link to docket
Biologic Drugs cited in Barkan Wireless IP Holdings, L.P. v. Samsung Electronics Co., Ltd.
The biologic drug covered by the patent cited in this case is ➤ Try a Free Trial .

Details for Barkan Wireless IP Holdings, L.P. v. Samsung Electronics Co., Ltd. (E.D. Tex. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-12-21 80 information therein as discussed at 10:41-44 of the ’312 patent. Indeed, the statement that the “black…terms of U.S. Patent Nos. 8,014,284 (the “’284 patent”), 8,559,312 (the “’312 patent) and 9,392,6389,392,638 (the “’638 patent”) (collectively, the “Asserted Patents” or “Patents-in-Suit”). Specifically, I have…of the claims as well as the entire patent, including the patent specification and figures. I also understand…than the term “gateway” used in the ’284 patent and ’312 patent claims is used to avoid External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
McKinsey
UBS
Boehringer Ingelheim
Moodys
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.